CLINICAL OUTCOME OF COLORECTAL-CANCER PATIENTS TREATED WITH HUMAN MONOCLONAL ANTIIDIOTYPIC ANTIBODY
CLINICAL OUTCOME OF COLORECTAL-CANCER PATIENTS TREATED WITH HUMAN MONOCLONAL ANTIIDIOTYPIC ANTIBODY
复制标题
DOI：
10.1002/ijc.2910570103
复制
发表时间：
1994-04-01
影响因子：
6.4
通讯作者：
ROBINS, RA
中科院分区：
文献类型：
--
作者：
DENTON, GWL;DURRANT, LG;ROBINS, RA
已经开发出一种人单克隆抗独特型抗体（105AD7），它可以模拟结直肠肿瘤相关抗原，并在动物体内诱导细胞抗结直肠肿瘤免疫反应。 13 名晚期结直肠癌患者接受了 105AD7 免疫，并将他们的生存率与同时代具有类似疾病状态的未免疫患者组进行了比较。没有发现与抗独特型免疫相关的毒性。淋巴细胞对 gp72 阳性肿瘤细胞的增殖以及白细胞介素 2 的产生表明细胞对抗独特型免疫的反应；未检测到抗肿瘤抗体。免疫患者确诊晚期疾病后的中位生存期为 12 个月，而未免疫患者的中位生存期为 4 个月。本研究中免疫患者的生存率得到改善，且没有相关毒性，这表明 105AD7 免疫可能在结直肠癌的免疫治疗中具有相当大的潜力。 (C) 1994 年 Wiley-Liss 公司
A human monoclonal anti-idiotypic antibody (105AD7) has been developed which mimics a colorectal-tumour-associated antigen and induces cellular anti-colorectal tumour immune responses in animals. Thirteen patients with advanced colorectal cancer were immunized with 105AD7 and their survival was compared with that of a contemporary group of unimmunized patients with similar disease status. No toxicity related to anti-idiotype immunization was seen. Cellular responses to anti-idiotypic immunization were indicated by lymphocyte proliferation to gp72-positive tumour cells, and production of interleukin-2; anti-tumour antibodies were not detected. Median survival following diagnosis of advanced disease of immunized patients was 12 months, compared with 4 months in unimmunized patients. The improved survival of immunized patients in this study without associated toxicity suggests that 105AD7 immunization may have considerable potential for immunotherapy of colorectal cancer. (C) 1994 Wiley-Liss, Inc.